Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable. This new drug promises better adherence and wider access, especially in Telangana and Andhra Pradesh, helping India fight HIV and move closer to ending AIDS
According to the study, after infection, HIV becomes a part of an infected person's DNA forever, and in most cases, infected cells are silent and do not replicate the virus.
